^
    Back
    Association details:
    Biomarker:MSI-H/dMMR + PD-L1 expression
    Cancer:Cholangiocarcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Transl Med
    Title:

    Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience

    Excerpt:
    Two patient samples (1.6%) had MSI-H signatures, and the immunohistochemical results for PD-L1 were negative in patient sample A and positive (1%) in patient sample B...a 46-year-old male with a history of HBV infection, and he was diagnosed with local advanced left lobe massive cholangiocarcinoma...After 4 cycles of pembrolizumab treatment, the tumor was deemed stable and shrank by 7%...
    DOI:
    https://dx.doi.org/10.1186%2Fs12967-020-02437-2